Bio + Health

Investing in General Medicine

Vineeta Agarwala, Jorge Conde, Daisy Wolf, and Eva Steinman Posted October 6, 2026

Taxis and Toadstools (1926)

When we shop for almost anything, we expect three things: (1) to understand our options, (2) to see what they cost, and (3) to get what we need quickly. Technology has enabled entire industries to rebuild themselves around making this experience easier for consumers.

Then, we get to healthcare. Consumers don’t shop for healthcare, right? They don’t even know what they need, right (…said a patronizing voice)? In today’s era of pervasive LLMs, we have to acknowledge that patients do often know what they need. And the healthcare shopping experience has only become that much more frustrating as a result. Because even when we know what we need (a prescription renewal, a lab test, a scan, a specialist’s opinion), the work is just beginning. First find someone who offers care, then check whether insurance covers it, then track down our medical records, get the referral, figure out what prior authorization is, call the office to schedule, and then call again. And often, we learn what the whole thing costs only after receiving care.

Healthcare has many sophisticated systems for authorizing services and reimbursing providers. But the information a patient needs to actually make a purchasing decision is scattered across portals, phone calls, and paperwork. To the broader system, these are separate tasks owned by separate parties but to the person looking for care, they are all part of one deeply personal and consequential journey.

We couldn’t be more excited to lead General Medicine’s $120M Series B as they build the general store for healthcare.

Imagine finding a lump in your breast and wondering if it could be cancer. Getting an answer may involve an initial clinical evaluation with a primary care provider, followed by a diagnostic mammogram or ultrasound, and, depending on the findings, perhaps an image-guided biopsy. Then you nervously wait for someone to review the results with you. If it is cancer, the coordination gets far more complex: further imaging, separate appointments with surgical, medical, and radiation oncology teams – sometimes across different practices and locations. And on top of worrying about your health, you’re also the one ultimately responsible for keeping your care moving along.

Several changes are making a more connected experience possible today. Better access to medical records allows a person’s history to be brought together across providers and time, while AI can now synthesize that information and surface it in a way that is relevant to a specific need in the blink of an eye. But knowing what help you need is not the same as getting it. Acting on clinical guidance still means finding the right service, understanding what it costs, and often showing up to a physical appointment in the real world.

General Medicine is built on the belief that facilitating access to care is a core part of delivering it. The company brings patient history, ongoing clinical guidance, transparent pricing, and help accessing care into one experience. Its own medical group combined with a marketplace of external clinicians (including both primary care physicians and specialists) connect patients almost immediately with services far beyond what a single practice could ever provide. 

For the patient who found a lump: in the General Medicine experience, her prior mammograms from when she lived in a different city, the fact that her breast tissue requires MRI for screening, her symptoms today, the imaging she needs now, the specialist visit, the follow-up, and the cost of all this care given her current insurance coverage are all in one place from the very beginning.

Building the healthcare store starts with a basic question: what is being sold? In healthcare, this has never had a clean answer, since the same service can be described differently by a patient, a physician, an insurer, and a lab. General Medicine resolves these differences into the infrastructure underneath the store: a catalog of over 2,900 products and services across medications, labs, imaging, specialist consultations, and select in-person visits and procedures.

This matters just as much for everyday care. You might first try General Medicine for a prescription refill. If you later need lab work or a specialist’s opinion, you have somewhere to return that already has your history, medications, and insurance information. Each interaction adds to the scaffolding for the next. And for someone managing an ongoing condition, it becomes the first place they turn for care all year long. As General Medicine’s catalog grows to include more and more patient needs, it earns a larger share of a consumer’s care (and their healthcare spending, over which they feel control for the first time).

Alongside its direct consumer offering, General Medicine is also building for the enterprise. All incumbent healthcare institutions – health systems, payors, pharmacies, and more – are recognizing the urgent need to give their patients and members a world class shopping experience. The same underlying infrastructure for clinical guidance, transparent pricing, and rapid access that General Medicine has already built can be ‘turned on’ for consumers in partnership with any number of enterprise organizations.

We’re thrilled that the PillPack team is back together. TJ Parker, Elliot Cohen, and Ashwin Muralidharan pair deep product understanding with profound industry knowledge and experience. Together, they’re building the next generation of healthcare, and finally answering the question at the heart of every great general store: “What can I do for you today?”

About the Contributors
Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Crypto

new Investing in Conway, the Creator of Underdog

Chris Dixon, Gabriel Vasquez, and Elizabeth Harkavy
Infra

new Investing in doxxnet

Joel de la Garza and Martin Casado
Growth

new Investing in Armadin

David George and Stephenie Zhang
Consumer

Investing in Highstock

Olivia Moore and Justine Moore

Expert News by a16z

We have built a network of experts who are deeply rooted in technology and how it’s shaping our future. Subscribe to our newsletters to receive their perspectives.

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.